Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Masquelier

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|July 6, 2000
Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study GroupV Le Moing, G Chêne, B Masquelier, et al.
AIDS (London, England)|November 1, 1992
Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titresC Tamalet, B Masquelier, F Ferchal, et al.
The Journal of Infectious Diseases|October 21, 1998
Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors?F Boralevi, B Masquelier, M Denayrolles, et al.
Virology|July 16, 1999
Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8D Lang, W Hinderer, M Rothe, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2011
Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97AS Reigadas, B Masquelier, C Calmels, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 1, 1995
Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosineB Masquelier, I Pellegrin, A Ruffault, et al.
Journal of Global Antimicrobial Resistance|November 23, 2016
NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatmentA G Marcelin, B Visseaux, M Wirden, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 15, 1996
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loadsI Pellegrin, E Legrand, D Neau, et al.
Pediatric Dermatology|July 8, 2000
Asymmetric periflexural exanthem of childhood: microbiologic case-control studyD Coustou, B Masquelier, M E Lafon, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1991
In vitro assays show a dissociation of reverse transcriptase activity and core antigen (p24) production in two HIV-1 isolates from a patient receiving long-term treatment with zidovudine (ZDV)B Masquelier, T Combeau, J D Poveda, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|July 6, 2000
Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study GroupV Le Moing, G Chêne, B Masquelier, et al.
AIDS (London, England)|November 1, 1992
Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titresC Tamalet, B Masquelier, F Ferchal, et al.
The Journal of Infectious Diseases|October 21, 1998
Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors?F Boralevi, B Masquelier, M Denayrolles, et al.
Virology|July 16, 1999
Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8D Lang, W Hinderer, M Rothe, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2011
Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97AS Reigadas, B Masquelier, C Calmels, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 1, 1995
Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosineB Masquelier, I Pellegrin, A Ruffault, et al.
Journal of Global Antimicrobial Resistance|November 23, 2016
NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatmentA G Marcelin, B Visseaux, M Wirden, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 15, 1996
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loadsI Pellegrin, E Legrand, D Neau, et al.
Pediatric Dermatology|July 8, 2000
Asymmetric periflexural exanthem of childhood: microbiologic case-control studyD Coustou, B Masquelier, M E Lafon, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1991
In vitro assays show a dissociation of reverse transcriptase activity and core antigen (p24) production in two HIV-1 isolates from a patient receiving long-term treatment with zidovudine (ZDV)B Masquelier, T Combeau, J D Poveda, et al.
Pageof 4